Skip to main content Skip to section navigation Skip to footer
Inhibikase Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
  • Pipeline
    • Overview
    • Risvodetinib (IkT-148009) for Parkinson’s Disease and GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • Scientific Publications
  • Clinical Trials
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Jun 21, 2023 8:05am EDT

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

May 30, 2023 8:05am EDT

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

May 16, 2023 7:45am EDT

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

May 15, 2023 8:30am EDT

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 08, 2023 8:05am EDT

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

May 04, 2023 8:05am EDT

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

Apr 26, 2023 8:00am EDT

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease

Apr 21, 2023 8:30am EDT

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

Mar 31, 2023 8:22am EDT

Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity

Mar 23, 2023 5:15pm EDT

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2023 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap